Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00110006 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No accrual

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisone
DRUG: vincristine sulfate
PROCEDURE: positron emission tomography
RADIATION: fludeoxyglucose F 18

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]